TCW Group’s ResMed RMD Stock Holding History

TCW Group’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$475K	Buy	2,439 +9	+0.4%	+$1.86K	﹤0.01%	501
2026 Q1	$545K	Buy	2,430 +118	+5%	+$29.4K	﹤0.01%	454
2025 Q4	$557K	Buy	+2,312	New	+$591K	﹤0.01%	450

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TCW Group's RMD Position: Q2 2026 in Review

TCW Group increased its ResMed (RMD) stake by 0.37% in Q2 2026, buying an estimated $1.86K and bringing the position to 2,439 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #501.

TCW Group first reported a position in RMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $557K in Q4 2025. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

TCW Group held 2,439 shares of ResMed worth $475K as of Q2 2026.
TCW Group bought 9 ResMed shares in Q2 2026, an estimated $1.86K.
ResMed made up ﹤0.01% of TCW Group's portfolio in Q2 2026, its #501 holding.
TCW Group first reported a position in ResMed in Q4 2025 and has held it in 3 quarters since.
TCW Group's ResMed position peaked at $557K in Q4 2025.
887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on TCW Group's 13F filing for Q2 2026, filed 3 Aug 2026.